Pemetrexed/Cisplatin is named as a drug or biological intervention in 2 clinical trials in our USA, Ireland, UK, India and China trial registers, 1 of which is recruiting. The lead sponsor is AstraZeneca. Registered phases: Phase 2 and Phase 3. Conditions studied include Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05061550 | Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer |
Phase 2 | Recruiting |
| NCT04035486 | A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non-small Cell Lung Cancer | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 2 |
| Register | Pemetrexed/Cisplatin trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in Ireland | 1 |
| Clinical trials in UK | 1 |
| Clinical trials in India | 1 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pemetrexed/Cisplatin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pemetrexed/Cisplatin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.